THE USEFULNESS OF PROSTATE SPECIFIC ANTIGEN SCREENING IN MALE PATIENTS PRESENTED WITH HAEMATURIA

KHALED HOSNY, MBBCH, MSC UROLOGY, MRCS, PGCME, FRCS Urology*
AHMED ABDELHAFEZ, MBBCH, MSC UROLOGY, MRCS*
THOMAS THOMPSON, MBCHB, MRCS*
OMAR W. S. AL-MULA ABED, MBCHB, MRCS, CHM, FABHS, FRCS*

Submitted 10 January 2019; accepted 19 May 2019

ABSTRACT

Background: In our study, we wanted to assess if prostate specific antigen (PSA) test is a useful test for patients presenting to our urgent clinics with Haematuria, or if it can be safely omitted, unless there were any clinical indication or after discussion with patients according to NICE guidelines.

Objective: Our objective is to review if the PSA test is a useful test that should be done routinely for all male patients presented to urgent clinic with haematuria in our practice in District hospital in UK.

Methods: We looked at retrospective data for 200 patients who presented with visible haematuria (VH) and non-visible haematuria (NVH) between 50-79 years old, between January 2016 and June 2017. All patients underwent digital rectal examination (DRE) and PSA testing as part of our standard investigation for haematuria.

Results: Out of 200 cases, 155 with visible haematuria, 10 of them underwent further investigations and two were diagnosed with prostate cancer and 45 with non-visible haematuria, 4 of them had further tests and none were diagnosed as prostate cancer. Overall number of patients who underwent further investigations is 14/200 (7%). Overall rate of prostate cancer diagnosis was 1%. The rate of diagnosis with visible haematuria 1.29%, and 0% with non-visible haematuria.

Conclusion: Despite using PSA as standard investigation for patients who are presented to urgent clinic with Haematuria, the rate of cancer diagnosis is very low (1%) and detected in patients with abnormal DRE, rather than elevated PSA. Our cancer detection rate 1% is less than those from ERSPC (8.2%), ProtecT (2.2%) and PLCO (1.4%). PSA should not be considered as a useful test of standard investigations for haematuria, unless abnormal DRE was found during examination.

Keywords: Haematuria – PSA test – Prostate cancer.

Haematuria is a not an uncommon problem which keeps urologist across the country very busy. It is estimated that around 2.6% of the population may experience it during their lifetime. Haematuria could be the first presentation to all urological cancers especially bladder cancer and to a lesser extent advanced and invasive prostate cancer, as well as to other benign conditions for example urinary tract infections, renal and ureteric stones. Haematuria is further classified into visible haematuria (VH) and non-visible haematuria (NVH). Non visible haematuria is defined as 3 or more red blood cells per high power field (HPF) in the absence of infection or proteinuria.

* Urology Department, East Lancashire Hospitals NHS Trust, Lancashire, United Kingdom.
Correspondence author: Omar W S Al-Mula Abed, omar.mulaabed@gmail.com, Mobil +447955529584

https://doi.org/10.31386/dmj.2019.12.1.1
PSA testing and screening has always been a controversial topic. There are three large randomised controlled trials (RCT) to assess the benefit of PSA screening; The European Randomised Study of Screening of Prostate cancer (ERSPC), The Prostate, Lung, Colorectal and Ovary cancer (PLCO), and ProtecT study. The long running ERSPC study updated their 13 years of follow up results and concluded that 781 males need screening to detect 27 cases and to prevent one death. The PLCO study showed a 4.9% overall rate of cancer detection. PLCO also showed no evidence of mortality evidence compared to opportunistic screening at 13 years of follow-up. Finally, the ProtecT study showed overall detection rate of 2.2%. The overall conclusion from PLCO and ProtecT showed no difference in the disease specific mortality amongst the screened group compared to the control group. The ERSPC in 13 years follow up, revealed reduction in prostate cancer mortality due to PSA testing compared to their findings at 9 and 11 years. Despite these findings, the recommended further assessment of pros and cons of PSA testing prior to introduction of population based screening.

NICE guidelines recommend the consideration of PSA and digital rectal examination in patients with visible haematuria. However, in view of the low detection rate and the low mortality rate in those three large RCTs, We retrospectively looked at our data to identify the usefulness of PSA testing in patients presenting with haematuria.

PATIENTS AND METHODS
We retrospectively examined data of 200 male patients aged 50-79 years presented to our urgent haematuria clinic with visible haematuria (VH) and non-visible haematuria (NVH) as their first presentation with no previous history of cancer between January 2016 and June 2017.

All patients were clinically assessed in a standardised manner with history and examination including digital rectal examination (DRE). They all underwent standard baseline investigations for haematuria, including urine dipstick, urine cytology, renal ultrasound scan, flexible cystoscopy, and blood tests including renal function tests and PSA. All patients had their PSA tested before DRE and flexible cystoscopy.

We followed the guidelines of the prostate cancer risk management programme (PCRMP) to identify elevated PSA. That was updated in 2015 revealed the high variability of age specific values related to difference in demographics and clinical characteristics in a certain population.

RESULTS
Out of the 200 cases included in our study 155 patients presented with VH and 45 presented with NVH. Of those with VH, 134 patients had benign DRE and normal PSA test results. The remaining 21 cases had one or two parameters abnormal. For the purpose of interpretation they were further analysed in three groups.

The first group included 17 patients who had a benign DRE with an elevated age specific PSA. 11 patients had symptoms...
suggesting urinary tract infection. They had a repeat PSA which came back within normal levels. Among the remaining 6 cases, two of them had chronically elevated PSA attributed to a large prostate gland. They continued to undergo Transurethral resection of prostate (TURP) which showed benign histology. The other 4 patients were investigated by MRI scan and only one of them proceeded to have Trans rectal ultrasound (TRUS) guided prostate Biopsy with negative malignancy results.

Table 1: PSA Results

<table>
<thead>
<tr>
<th>Age group</th>
<th>initial PSA mean</th>
<th>median</th>
<th>Repeat PSA mean</th>
<th>median</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 - 60</td>
<td>7.4</td>
<td>8</td>
<td>3.2</td>
<td>3.3</td>
</tr>
<tr>
<td>60 - 70</td>
<td>6.84</td>
<td>6.2</td>
<td>2.64</td>
<td>2.2</td>
</tr>
<tr>
<td>70 - 80</td>
<td>9.6</td>
<td>8.9</td>
<td>4.9</td>
<td>5.3</td>
</tr>
</tbody>
</table>

The second group included only one patient who had an abnormal DRE and an elevated PSA 11.8 microgram/L, which is above the age specific range; he underwent further investigations in form of MRI scan, which showed T4 N1 disease. He subsequently underwent TRUS guided prostate Biopsy to assess suitability for upfront chemotherapy and was confirmed to have a Gleason 8 prostate cancer.

The third group included three patients having abnormal DRE with normal age specific PSA, two of them underwent further investigations in form of TRUS guided prostate Biopsy and only one of them was diagnosed with Gleason 6 prostate cancer, the third case had MRI scan which suggested prostatitis, and no further action was taken of the 45 patients who presented with NVH all had a benign DRE and only 4 patients had an elevated PSA. Within those who had an elevated PSA Three were investigated by MRI scan and one of them had TRUS Biopsy with no malignancy found.

The overall number of patients who underwent further investigations was 14 of 200 total patients (7%). The overall rate of prostate cancer diagnosis was 1%. The rate of diagnosis with visible haematuria 1.29%, and 0% with non-visible haematuria.

Figure 1: Flow-Chart of Findings.
THE USEFULNESS OF PROSTATE SPECIFIC Antigen SCREENING IN MALE

DISCUSSION

Haematuria is one of the common urological presentations. The main causes of haematuria include urinary tract infection, urinary tract stones, trauma, renal parenchymal disease and urological cancers. The common primary urological cancers presenting with haematuria are renal cell carcinoma, urothelial carcinoma and prostate cancer. Early cases of prostate cancer are not expected to present with haematuria as they usually arise in peripheral zone of the prostate away from the urethra, however locally advanced cases are expected to cause haematuria and are mostly detected by DRE.

In the work by Catalona et al. 1994, where he compared the efficacy of DRE versus elevated PSA in early detection of prostate cancer. Elevated PSA detected more tumours (82%) than abnormal DRE (55%). When the two methods were combined, that increased the rate of detection of organ confined disease by 78% over DRE alone. In our work, despite using PSA as a standard investigation for patients who presented to urgent clinic with haematuria, the rate of cancer diagnosis is very low (1%) and detected in patients with abnormal DRE, rather than elevated PSA.

Our prostate cancer detection rate of 1% is less than those from ERSPC, ProtecT and PLCO. There are similar studies in the literature looking at prostate cancer detection rate in patients with haematuria. Khadra et al in 2000 did a study on 1930 patients with haematuria, 1194 of them were men. Their prostate cancer detection rate was 0.7%. Bromage et al in 2006 had an overall prostate cancer detection rate of 8% and 5.9% detection rate in men aged 50-79 in a study that contained 637 men. They recommended the use of PSA in clinical practice in the absence of prospective controlled trial at the time. However, Chandrasekharan et al in 2009 did a similar study in men presenting with haematuria to their urgent clinic. They included 749 men with an overall prostate cancer detection rate of 3.7%. They recommended not to routinely use PSA in clinical practice unless patients are appropriately counselled. The current NICE guidelines and European guidelines for PSA testing recommends consideration of the benefits and limitations of PSA testing before offering it to patients with suspected prostate cancer in the primary care. The current European guidelines (EAU) also recommended individualised risk-adapted strategy for early detection to well-informed men with good performance status and 10 to 15 years life expectancy.

In conclusion, PSA testing should not be considered as a part of standard investigations for haematuria, unless an abnormal DRE was found during examination and after careful discussion of the benefits and limitations of PSA testing with the patient.

CONFLICT OF INTEREST

The above work has been accepted and presented as a poster presentation in 7th Emirates urological conference and 15th Arab urological conference–November 2018. The abstract has been published subsequently in a supplement of the Arab journal of urology but not the main manuscript.
REFERENCES


CAFETINA: وآبيدوجونيك دل دور راد مفایین تاکیرنی دزکارا پروستاتا چؤریه (PSA) دنع مخوشین رهگرز نیر تیوین سمردان

کلینیکا ددرکی یا برک لنک مه کری ل نخوشخانت داهری و توشی میزا خوینهلوین بووین.

بی‌دوجون: ل داتایین 200 نه‌خوشان گر ی اوشازنگن فغمر کو گازندن‌ز میزا خوینهلو لیا دیار (VH) دکیان میزا خوینهلو

يا تاعیدار دکم، تدمیننی وان داکیریا 50 – 79 سالین بیو، داکیریا 2016 و 2017 همی نخوش کامته بمر بشکینن ریکیه (PSA) و تاکیرنی دزکارا پروستاتا چؤری (DRE) ودک بیکیکت ز بشکینی بیفرمر یا میزا خوینهلو. 

ز 200 حالتان 155 حالت توشی میزا خوینهلو لیا دیار بووین، 10. ز ین کامته بمر بشکیننها زیده و دوو ب پنمجشیرا پروستاتا هامنه دست نیشانکر. ین 45 حالتانی دی بهن توشی میزا خوینهلو بووین 4 ی ین کامته بمر تاکیرنی زیده و جوان ب پنمجشیرا پروستاتا هامنه دست نیشانکر.

تارمین‌ها: نم‌خوشین گامین یا دست نیشانکر دیب دش‌هیسته 100/4 (7 %)، ین تیکراگیکت دیب دست نیشانکر دیب دش‌هیسته 1/0 یا بوو داگل میزا خوینهلوهی نتیخ.

ل دوماهبات یا دست نیشانکر (PSA) دزکارا یا پروستاتا چؤری و تاکیرنی بیفرمر بو وان نخوشان نم‌خوشین نم‌خوشین گامنبکو وکن وکن پی‌سانده (DRE) دیب دست نیشانکروئی دیب خودنی دیاب (DRE) نم‌خوشین دزکارا پروستاتا چؤری (PSA) یا برد دش‌هیسته تیکراگیکت دیب دست نیشانکر 1/0 %، نم‌خوشین گامنبکو وکن وکن ین 0.0 برک لنک مه کری ل نخوشخانت داهری و توشی میزا خوینهلو

SERME: نم‌خوشین گامین یا دست نیشانکر دیب دش‌هیسته 2/0 (2.8) %، ین تیکراگیکت یا دست نیشانکر ین 4.1 (2.8) % ERSPC و ین 520 (2.8) % PLCO.

نم‌خوشین دزکارا پروستاتا چؤری (PSA) نم‌خوشین گامنبکو وکن وکن (PLCO) ین 1.5 (2.8) % و ین 520 (2.8) % ERSPC.

https://doi.org/10.31386/dmj.2019.12.1.1
THE USEFULNESS OF PROSTATE SPECIFIC Antigen SCREENING IN MALE

الخلاصة

فادئة فحص مستضد البروستاتا المحدد عند مرضاى الذين يعانون من البول الدموى (PSA) عند المرضاى الذكور الذين راجعوا إعادة الجراحية العاجلة لدينا بعد التشخيص ويعانون من بيئة دموية.

طرق البحث: قمنا بدراسة بيانات 200 مرضاى - باثر رجعي - وعند مرضاى من بيئة دموية مرتبطة (VH) أو بيئة دموية غير مرتبطة. معجر جميع المرضى لفحص المستقيم الاصبعى (DRE) واختبار مستضد البروستاتا النوعى (PSA) كجزء من الفحص المعيارلى للبيئة الدموية.

من بين 200 حالة، كان هناك 155 حالة مصابية ببيئة دموية مرتبطة خضع 10 منهم إلى مزيد من الفحوصات ومتم تشخيص اثنى بسرطان البروستاتا، أما 45 حالة أخرى ليسوا ببيئة دموية غير مرتبطة فقد خضع 4 منهم لمزيد من الاختبارات ولم يتم تشخيص أي منهم بسرطان البروستاتا.

النتائج: إن معدل اكتشاف السرطان لدينا 1% وهو أقل من معدله في (8.2%) ERSPC و (2.2%) ProtecT و (1.4%) PLCO. بناء عليه فلنا ينصح بإجراء اختبار مستضد البروستاتا النوعى (PSA) كمجرة اكتشاف مبكر للعوامل المعيارية للبيئة الدموية في حال عدم وجود فحص مستقيم أصبعى (DRE) غير طبيعي. 

الخلفية والأهداف: هدفنا هو مراجعة مدى فادئة اختبار مستضد البروستاتا النوعى (PSA) عند المرضاى الذكور الذين راجعوا إعادة الجراحية العاجلة لدينا بعد التشخيص ويعانون من بيئة دموية مرتبطة (VH) أو بيئة دموية غير مرتبطة. معجر جميع المرضى لفحص المستقيم الاصبعى (DRE) واختبار مستضد البروستاتا النوعى (PSA) كجزء من الفحص المعيارلى للبيئة الدموية.

من بين 200 حالة، كان هناك 155 حالة مصابية ببيئة دموية مرتبطة خضع 10 منهم إلى مزيد من الفحوصات ومتم تشخيص اثنى بسرطان البروستاتا، أما 45 حالة أخرى ليسوا ببيئة دموية غير مرتبطة فقد خضع 4 منهم لمزيد من الاختبارات ولم يتم تشخيص أي منهم بسرطان البروستاتا.

النتائج: إن معدل اكتشاف السرطان لدينا 1% وهو أقل من معدله في (8.2%) ERSPC و (2.2%) ProtecT و (1.4%) PLCO. بناء عليه فلنا ينصح بإجراء اختبار مستضد البروستاتا النوعى (PSA) كمجرة اكتشاف مبكر للعوامل المعيارية للبيئة الدموية في حال عدم وجود فحص مستقيم أصبعى (DRE) غير طبيعي.